SS18::SSX fusion (synovial sarcoma)
Every true synovial sarcoma carries a fusion between the SS18 gene on chromosome 18 and an SSX gene on the X chromosome; finding it by FISH, RNA sequencing or a newer antibody stain confirms a diagnosis that pathologists otherwise struggle with, and it also flags the tumour for the MAGE-A4 and NY-ESO-1 cell therapies that work almost only in this disease.
Overview
What is measured: the SS18::SSX fusion from t(X;18)(p11;q11). How: FISH with an SS18 break-apart probe, RT-PCR or targeted RNA sequencing naming the partner (SSX1 in about two-thirds, SSX2 in a third, SSX4 rarely), or immunohistochemistry with the fusion-specific SS18-SSX antibody (about 95 percent sensitive and near 100 percent specific) and the SSX C-terminus antibody; TLE1 staining is a sensitive but less specific screen. The fusion protein hijacks the BAF (SWI/SNF) chromatin-remodelling complex and displaces SMARCB1, which is why the tumours are partly INI1-deficient; a poorly differentiated component and size over 5 cm worsen the outlook. About 70 percent express MAGE-A4 and 80 percent NY-ESO-1, cancer-testis antigens. What a result changes: it settles the diagnosis against MPNST, solitary fibrous tumour, Ewing sarcoma and poorly differentiated carcinoma; synovial sarcoma is more chemosensitive than most sarcomas (ifosfamide with doxorubicin); with MAGE-A4 immunohistochemistry and HLA-A*02 typing it qualifies patients for afamitresgene autoleucel (approved 2024) and NY-ESO-1-directed letetresgene autoleucel; BRD9 degraders and other BAF-directed drugs are in trials. Where it matters: synovial sarcoma.
Similar pages
not linked directly; found by shared links- TermFOXO1 fusion status and IRS group (rhabdomyosarcoma)
Shares FISH / ISH (in situ hybridisation), Ifosfamide, Gene fusion, RNA sequencing & expression profiling.
- TrialSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Shares Afamitresgene autoleucel, Synovial sarcoma.
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares MAGE-A4, Afamitresgene autoleucel.
- PersonSandra P. D'Angelo
Shares MAGE-A4, Afamitresgene autoleucel.
- Key paperEORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma
Shares Synovial sarcoma, Ifosfamide, Doxorubicin.
- PersonArul M. Chinnaiyan
- TermUveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)
Shares HLA-A*02:01 restriction, FISH / ISH (in situ hybridisation).
- TrialINT-0091 (Ewing sarcoma)
Shares Ifosfamide, Doxorubicin.